BrainsWay Advances Deep Transcranial Magnetic Stimulation for Major Depressive Disorder

Global medical technology company, BrainsWay Ltd. (Nasdaq: BWAY), has initiated a prospective, randomized, controlled, multicenter clinical trial evaluating an accelerated treatment protocol for the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) system to treat major depressive disorder (MDD). The company’s share price settled up +3.42% on Monday following the news.

BrainsWay is currently recruiting patients for its prospective, randomized, controlled, multicenter study at multiple clinical sites throughout the US. The trial is anticipated to enroll 100 patients with major depressive disorder (MDD) who will be split into two groups – one receiving a novel accelerated treatment protocol featuring an acute phase over several treatment days, and the other receiving the FDA-cleared standard-of-care protocol which entails an acute phase over several weeks.

Commenting on the trial, Colleen Hanlon, PhD, Vice President of Medical and Clinical Affairs of BrainsWay, said, “We are excited to begin this important clinical trial. Previously published post-marketing data has shown outcomes achieved with accelerated protocols to be comparable with those from longer, traditional protocols. We seek to explore this hypothesis more conclusively during this multicenter study.”

MDD is one of the most common mental illnesses. Approximately 21 million American adults had a depressive episode in 2021, according to the National Institute of Mental Health (NIMH).

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.